GLP-1RAs reduce weight and HbA1c in severe mental illness with low discontinuation rates

This systematic review and meta-analysis examined the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in individuals with severe mental illness (SMI) who have prediabetes or are overweight or obese. The analysis included data from 10 trials with a total sample size of N = 665 participants. The setting was not reported in the source data. The intervention involved GLP-1RAs, while the comparator was placebo or usual care. The study type is a systematic review and meta-analysis, and the publication type matches this classification. The phase of the evidence was not reported.

The primary outcomes assessed were weight reduction, glycated hemoglobin (HbA1c) reduction, all-cause dropouts, and adverse effect dropouts. Results for weight reduction were significantly reduced with a mean difference (MD) of 6.17 kg. This finding was based on 9 trials. The 95% confidence interval for weight reduction was 9.10 to 3.25. Results for HbA1c reduction were slightly reduced with a mean difference of 0.31%. This outcome was derived from 8 trials. The 95% confidence interval for HbA1c reduction was 0.40 to 0.22.

Regarding discontinuation rates, all-cause dropouts did not differ significantly between the intervention and comparator groups. The relative risk (RR) was 0.98 based on 10 trials. The 95% confidence interval for all-cause dropouts was 0.71 to 1.35. Adverse effect dropouts also did not differ significantly. The relative risk was 0.99 based on 5 trials. The 95% confidence interval for adverse effect dropouts was 0.35 to 2.77. No p-values were explicitly provided for these specific comparisons in the input data beyond the confidence intervals.

Safety and tolerability findings indicate that low certainty evidence supports tolerability. Specific adverse events, serious adverse events, and discontinuations were not reported in the input data. The certainty note states that low certainty evidence supports the tolerability and efficacy of GLP-1RAs for weight and HbA1c reduction. Moderate certainty evidence also supports their acceptability. The input data does not provide specific adverse event rates or detailed safety profiles beyond the dropout analysis.

Comparison to prior landmark studies is not detailed in the input text, so specific historical context cannot be fabricated. The input data does not list secondary outcomes beyond the primary ones. Methodological limitations and potential biases were not reported in the input JSON. Funding or conflicts of interest were not reported. The practice relevance was not reported in the source material.

Clinical implications suggest that GLP-1RAs may offer a viable option for weight and glycemic management in this population, given the significant weight reduction and lack of significant difference in dropout rates. However, the low certainty of evidence for tolerability and the moderate certainty for acceptability require cautious interpretation. Questions remain unanswered regarding long-term safety, specific adverse event profiles, and optimal dosing protocols for patients with complex psychiatric comorbidities. The lack of reported setting details limits the generalizability of the findings to specific clinical environments.